Recent progress in the therapeutic management of pre-eclampsia

Bibliography

• FISHER KA, LUGER A, SPARGO BH, LINDHEIMER MD: Hypertension in pregnancy: clinical-pathological correlations and late prognosis. Medicine (Baltimore) (1981) 60:267–276.
   PubMed Web of Science ®Google Scholar
• IHLE BU, LONG P, OATS J: Early-onset pre-eclampsia: recognition of underlying renal disease. Br. Med. J. (1987) 294:79–81.
   PubMed Web of Science ®Google Scholar
• MUSHAMBI MC, HALLIGAN AW, WILLIAMSON K: Recent developments in the pathophysiology and management of pre-eclampsia. Br. Anaesth. (1996) 76:133–148.
   PubMed Web of Science ®Google Scholar
• SIBAI BM, SPINNATO JA, WATSON DL et al.: Pregnancy outcome in 303 cases with severe pre-eclampsia. Obstet. Gynecal. (1984) 64:319–325.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM FG, LINDHEIMER MD: Hypertension in pregnancy [see comments]. N Engl. J. Med. (1992) 326:927–932.
   PubMed Web of Science ®Google Scholar
• SIBAI BM: Pitfalls in diagnosis and management of pre-eclampsia. Jim. Obstet. Gynecal. (1988) 159:1–5.
   PubMed Web of Science ®Google Scholar
• DEKKER GA, SIBAI BM: Aetiology and pathogenesis of pre-eclampsia: current concepts. Am. Obstet. Gynecal. (1998) 179:1359–1375.
   PubMed Web of Science ®Google Scholar
• SIBAI BM, RAMADAN MK, USTA I et al.: Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Jim. .1 °Enter Gynecal. (1993) 169:1000–1006.
   Google Scholar
• SIBAI BM, TASLIMI MM, EL-NAZER Aet al.: Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe pre-eclampsia-eclampsia. Am. °Enter Gynecal. (1986) 155:501–509.
   Google Scholar
• HARMS K, PATH W, HERTING E, KUHN W: Maternal hemolysis, elevated liver enzymes, low platelet count, and neonatal outcome. Am. Perinatal (1995) 12:1–6.
   PubMed Web of Science ®Google Scholar
• VILLAR MA, SIBAI BM: Clinical significance of elevated mean arterial blood pressure in second trimester and threshold increase in systolic or diastolic blood pressure during third trimester [see comments]. Am. Obstet. Gynecal. (1989) 160:419–423.
   PubMed Web of Science ®Google Scholar
• BELLOMO G, NARDUCCI PL, RONDONI F et al.: Prognostic value of 24-hour blood pressure in pregnancy. JA/VIA (1999) 282:1447–1452.
   Google Scholar
• SAFTLAS AF, OLSON DR, FRANKS AL et al.: Epidemiology of pre-eclampsia and eclampsia in the United States, 1979-1986. Am. J. Obstet. Gynecal. (1990) 163:460–465.
   PubMed Web of Science ®Google Scholar
• PACKHAM DK, MATHEWS DC, FAIRLEY KF et al: Morphometric analysis of pre-eclampsia in women biopsied in pregnancy and post-partum. Kidney Int (1988) 34:704–711.
   PubMedGoogle Scholar
• SIBAI BM, EL-NAZER A, GONZALEZ-RUIZ A: Severe pre-eclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am. Obstet. Gynecal. (1986) 155:1011–1016.
   PubMed Web of Science ®Google Scholar
• SIBAI BM, MERCER B, SARINOGLU C:Severe pre-eclampsia in the second trimester: recurrence risk and long-term prognosis. Am. .1 °Enter Gynecal. (1991) 165:1408–1412.
   Google Scholar
• SIBAI BM, SARINOGLU C, MERCER BM: Eclampsia. VII. Pregnancy outcome after eclampsia and long-term prognosis. Am. J. °Enter Gynecal. (1992) 166:1757–1761.
   Google Scholar
• HELEWA ME, BURROWS RF, SMITH J et al.: Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy CMAI (1997) 157:715–725.
   Google Scholar
• ROBERTS JM, REDMAN CW: Pre-eclampsia: more than pregnancy-induced hypertension. Lancet (1993) 341:1447–1451.
   PubMed Web of Science ®Google Scholar
• MEEKINS JW, PIJNENBORG R, HANSSENS M et al: A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br. Obstet. Gynaecal. (1994) 101:669–674.
   PubMedGoogle Scholar
• FRIEDMAN SA, LUBARSKY SL, AHOKAS RA et al.: Pre-eclampsia and related disorders. Clinical aspects and relevance of endothelin and nitric oxide. Clin. Perinatal. (1995) 22:343–355.
   Google Scholar
• ZHOU Y, DAMSKY CH, CHIU K et al.:Pre-eclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. Clin. Invest. (1993) 91:950–960.
   Google Scholar
• GENBACEV 0, DIFEDERICO E, MCMASTER M, FISHER SJ: Invasive cytotrophoblast apoptosis in pre-eclampsia. Hum. Reprod. (1999) 14\(Suppl. 2):59–66.
   Google Scholar
• SMITH G, WALKER M, TESSIER J, MILLAR K: Increased incidence of pre-eclampsia in women conceiving by intrauterine insemination with donor versus partner sperm for treatment of primary infertility. Am. °Enter Cynecol (1997) 177:455–458.
   PubMed Web of Science ®Google Scholar
• GRANGER JP, ALEXANDER BT, LLINAS MT et al.: Pathophysiology of hypertension during pre-eclampsia linking placental ischemia with endothelial dysfunction. Hypertension (2001) 38(2):718–722.
   PubMedGoogle Scholar
• GREER IA: Haemostasis and thrombosis in pregnancy. In: Haemostasis and thrombosis (3rd Edn) Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (Eds). Churchill Livingstone, Edinburgh, UK (1994):987–1015.
   Google Scholar
• SORENSEN JD, SECHER NJ, JESPERSEN J: Perturbed (procoagulant) endothelium and deviations within the fibrinolytic system during the third trimester of normal pregnancy. Acta °Enter Cynecol Scand. (1995) 74:257–261.
   PubMed Web of Science ®Google Scholar
• SCHJETLEIN R, HAUGEN G, WISLOFF F: Markers of intravascular coagulation and fibrinolysis in pre-eclampsia: association with intrauterine growth retardation. Acta °Enter Cynecol Scand. (1997) 76:541–546.
   PubMed Web of Science ®Google Scholar
• BALLEGER V, SPLITZ B: Predictive value of increased levels of fibronectin in gestational hypertension. Jim. °Enter Cynecol (1989) 16:432–436.
   Google Scholar
• FREBELIUS S, HEDIN U, SWEDENBORG J: Thrombogenicity of the injured vessel wall role of antithrombin and heparin. Thromb. Haemost. (1994) 71(I):147–153.
   Google Scholar
• CHEN J, ISHII M, WANG L, ISHII K, COUGHLIN SR: Thrombin receptor activation. J. Biol. Chem. (1994) 269(23):16041–16045.
   PubMedGoogle Scholar
• RBIET MJ, PLANTIER JL, DEJANA E: Thrombin-induced endothelial cell dysfunction. Br. Med. Bull. (1994) 50:936–945.
   PubMedGoogle Scholar
• KOBAYASHI T, TERAO T: Pre-eclampsiaas chronic disseminated intravascular coagulation. Cynecol Obstet. Inves. (1987) 24:170–178.
   PubMed Web of Science ®Google Scholar
• PEZZY KG, MARTIN JM: Abnormal haemostasis and coagulopathy in pre-eclampsia and eclampsia. Clin. Obstet. Cynecol (1992) 35:338–350.
   PubMedGoogle Scholar
• MARTIN JN, PERRY KG, BLAKE PG et al.: Better maternal outcomes are achieved with dexamethasone therapy for postpartum HELLP (hemolysis, elevated liver enzymes, and thrombocytopenia) syndrome. Jlm.j °Enter Cynecol (1997) 177:1011–1017.
   PubMed Web of Science ®Google Scholar
• MAGANN EF, BASS D, CHAUHAN SP et al.: Anterpartum corticosteroids: disease stabilization in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am. I Obstet. Cynecol (1994) 171:1148–1153.
   PubMed Web of Science ®Google Scholar
• Diagnosis and management of preeclampsia and eclampsia. ACOG Bulletin n.33. Washington DC: American College of Obstetricians and Gynecologists (2002).
   Google Scholar
• KWAWUKUME EY, GHOSH TS: Oral nifedipine therapy in the management of severe pre-eclampsia. Int. Cynecol °Enter (1995) 49:265–269.
   Google Scholar
• WACKER J, WERNER P, WALTER-SANK I, BASTERT G: Treatment of hypertension in patients with pre-eclampsia: a prospective parallel-group study comparing dihydralazine with urapidil. Nephrol Dial. Transpl. (1998) 13:318–325.
   PubMedGoogle Scholar
• SIBAI BM: Prevention of pre-eclampsia: a big disappointment. Am. .1. °Enter Cynecol (1998) 179:1275–1278.
   PubMed Web of Science ®Google Scholar
• MAGEE LA, ORNSTEIN MP, VON DADELSZEN P: Fortnightly review: management of hypertension in pregnancy. Br. Med. (1999) 318:1332–1336.
   PubMed Web of Science ®Google Scholar
• REMUZZI G, RUGGENENTI P: Prevention and treatment of pregnancy-associated hypertension: what have we learned in the last 10 years? Am. Kidney Dis. (1991) 18:285–305.
   PubMed Web of Science ®Google Scholar
• The Sixth Report of the Joint National Committee on Detection, Evaluation, and Diagnosis of High Blood Pressure. (JNC VI). Arch. Intern. Med. (1997) 157:2413–2446.
   PubMedGoogle Scholar
• EASTERLING TR, CARR DB, BRATENG D, DIEDERICGS C, SCHMUCKER B: Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. °Enter Cynecol (2001) 98:427–433.
   Google Scholar
• MAGEE LA, CHAM C, WATERMAN EJ, OHLSSON A, VON DADELSZEN P: Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. Br. Med. J. (2003) 327:955–960.
   PubMed Web of Science ®Google Scholar
• MAGEE LA, ORNSTEIN MP, VON DADELSZEN P: Management of hypertension in pregnancy. Br. Med. (1999) 318:1332–1336.
   PubMed Web of Science ®Google Scholar
• SIBAI BM, TASLIMI M, ABDELLA TN et al.: Maternal and perinatal outcome of conservative management of severe pre-eclampsia in midtrimester. Am. Obstet. Cynecol (1985) 152:32–37.
   PubMed Web of Science ®Google Scholar
• [No authors listed] Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet (1995) 345:1455–1463.
   Google Scholar
• LUCAS MJ, LEVENO KJ, CUNNINGHAM FG: A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia N Engl. I Med. (1995) 333:201–205.
   Google Scholar
• PERRY KG, MARTIN JN: Abnormal hemostasis and coagulopathy in pre-eclampsia and eclampsia. Clin. Obstet. Cynecol (1992) 35:338–350.
   PubMed Web of Science ®Google Scholar
• RABIET MJ, PLANTIER JL, DEJANA E: Thrombin-induced endothelial cell dysfunction. Br. Med. Bull. (1992) 50:936–965.
   Google Scholar
• HARPEL PC: Blood proteolytic enzyme inhibitors: their role in modulating blood coagulation and fibrinolytic enzyme pathways. In: Hemostasis and Thrombosis Colman RW, Hirsh J, Marder VJ, Saizman EW (Eds) J.B. Lippincott, Philadelphia, USA (1982):738–741.
   Google Scholar
• ROSENBERG RD, DAMUS PS: The purification and mechanism of action of human antithrombin-heparin cofactor. J. Biol. Chem. (1973) 248:6490–6495.
   PubMed Web of Science ®Google Scholar
• SHINYAMA H, AKIRA T, UCHIDA T et al.: Antithrombin III prevents renal dysfunction and hypertension induced by enhanced intravascular coagulation in pregnant rats: pharmacological confirmation of the benefits of treatment with antithrombin III in pre-eclampsia. Cardiovasc. Phann. (1996) 27:702–711.
   PubMedGoogle Scholar
• MAID M, TERAO T, IKENOUE T et al: Clinical evaluation of antithrombin III concentrate (BI6.013) for disseminated intravascular coagulation in obstetrics. Cynecol Obstet. Invest. (1987) 23:230–240.
   PubMedGoogle Scholar
• FUJIWARA K, OKITA K, AKAMATSU K et al.: Antithrombin III concentrate in the treatment of fulminant hepatic failure. Castreenterel fpn. (1988) 23:423–427.
   Google Scholar
• MAKI M, TERAO T, IKENOUE T et al: Clinical evaluation of antithrombin III concentrate for disseminated intravascular coagulation in Obstetrics. Cynecel Obstet. haves. (1987) 23:230–240.
   Google Scholar
• BAUDO F, CAIMI TM, DE CATALDO F et al.: Antithrombin III (AT III) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Car. Med. (1998) 24:336–342.
   Google Scholar
• BICK RL: Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin. Thremb Herne. (1998) 24:3–18.
   PubMed Web of Science ®Google Scholar
• MAMMEN EF: Antithrombin: Its physiological importance and role in DIC. Semin. Thremb. Hemest. (1998) 24:19–25.
   PubMedGoogle Scholar
• TERAO T, KOBASHI T, IMAI N: Pathological state of the coagulatory and fibrinolitic system in pre-eclampsia and the possibility of its treatment with AT III concentrate. Asia Oceania J. °Enter Cynaecel (1989) 15:25.
   PubMedGoogle Scholar
• MANGIONE S, GIARRATANO A: The role of ATIII in critical patients in obstetrics. Minerva Anestesiel (2002) 68(5):449–453.
   PubMedGoogle Scholar
• MAKI M, KOBAYASHI T, TERAO T et al.: Antithrombin therapy for severe pre-eclampsia. Thremb. Haemest. (2000) 84:583–590.
   PubMedGoogle Scholar
• PATERNOSTER DM, FANTINATO S, MANGANELLI F et al.: Efficacy of AT in pre-eclampsia: a case control prospective trial. Thremb. Haemest. (2004) 91:283–289.
   PubMed Web of Science ®Google Scholar
• WEINER CP, HERRIG JE, PELZER GD, HEILSKOV J: Elimination of antithrombin III concentrate in healthy pregnant and preeclamptic woman with an acquired antithrombin III deficiency. Thremb. Res. (1990) 58:395–401.
   PubMedGoogle Scholar
• SIBAI BM, RAMADAN MK, USTA I et al.: Maternal morbidity and mortality in 442 pregnancies with hemolysis, liver enzymes, ad low platelets (HELLP syndrome. Am. J. °Enter Cynecel (1993) 169(4):1000–1006.
   PubMed Web of Science ®Google Scholar
• FAIRLEY KF, ADEY FD, ROSS IC, KINCAID-SMITH P: Heparin treatment in severe pre-eclampsia and glomerulonephritis in pregnancy. Perspect. Nephrel Hypertens. (1976) 5:103–112.
   PubMedGoogle Scholar
• RIYAZI N, LEEDA M, DE VRIES JI et al.:Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of pre-eclampsia or foetal growth restriction: a preliminary study. Eur. I Obstet. Cynecel Repred. Biel (1998) 80:49–54.
   Google Scholar
• HOWIE PW, PRENTICE CR, FORBES CD: Failure of heparin therapy to affect the clinical course of severe pre-eclampsia. Br.j Obstet. Cynaecel (1975) 82:711–717.
   PubMedGoogle Scholar
• NAKABAYASHI M, ASAMI M, NAKATANI A: Efficacy of antithrombin replacement therapy in severe early-onset pre-eclampsia. Semin. Thremb. Hemest. (1999) 25:463–466.
   PubMedGoogle Scholar